Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Adult growth hormone deficiency in childhood cancer survivors
Completed
- Conditions
- 10021112growth hormone deficiency in childhood cancer survivorslate pituitary growth hormone deficiency effects of treatment for childhood cancer
- Registration Number
- NL-OMON47806
- Lead Sponsor
- Stichting Kinderoncologie Nederland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1500
Inclusion Criteria
treated with radiotherapy. Age >= 18 years, >= 5 years off tumor treatment, on
stable concomitant medications for 1 month prior to entry of study, otherwise
normal pituitary function or on stable hormonal replacement, no treatment for
growth hormone deficiency at the time of the tests
Exclusion Criteria
pregnancy, active neoplasm, abnormal pituitary functions or recently started
concomitant medications
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* Objective 1: free/bioactive, total IGF-1 concentrations, and their age and<br /><br>gender corrected standard deviation score (SDS-score).<br /><br>* Objective 2: diagnostic accuracy of free and total IGF-1 concentrations in<br /><br>the identification of growth hormone deficiency.</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>